MULTIPLE SCLEROSIS Update

Similar documents
MRI in Differential Diagnosis. CMSC, June 2, Jill Conway, MD, MA, MSCE

THE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY

SUSPECTED MECHANISMS INVOLVED IN MS AND PUTATIVE INTERACTIONS WITH HEPATITIS B VACCINE IN MS

MULTIPLE SCLEROSIS - REVIEW AND UPDATE

Hot Topics Multiple Sclerosis. Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018

MRI and differential diagnosis in patients suspected of having MS

Unraveling the Mystery of MS Differential Diagnosis

Disclosures. Biogen Idec Novartis Acorda Genzyme Roche Pfizer

Demyelinating Diseases: Multiple Sclerosis January 10, 2018 Dr. Ostrow

Difficult Diagnosis: Case History. 7 months prior, she happened to have undergone a C-spine MRI after a car accident

DOWNLOAD OR READ : MULTIPLE SCLEROSIS THE HISTORY OF A DISEASE PDF EBOOK EPUB MOBI

Disease of Myelin. Reid R. Heffner, MD Distinguished Teaching Professor Emeritus Department of Pathology and Anatomy January 9, 2019

PATIENT INFORMATION: Patient Surname First Name Middle Initial Sex Date of Birth Alberta Personal Health Number M / F Year Month Day

Neuroimaging and Other Biomarkers. MRI for Diagnosis, Prognosis and Treatment Decisions in MS

Progress in MS: Current and Emerging Therapies. Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada

THE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY

CHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island

Pediatric acute demyelinating encephalomyelitis in Denmark: a nationwide population-based study

Multiple sclerosis. Tünde Csépány MD. PhD

International IBD Genetics Consortium

Seema Sikka, MD January 18, 2014 TRANSVERSE MYELITIS: A CLINICAL OVERVIEW

Epidemiology, Diagnosis, Natural History & Clinical Course

The Role of MRI in Multiple Sclerosis

Helpful Information for evaluation of new neurological symptoms in patients receiving TYSABRI

The Impact of Multiple Sclerosis in the. James Bowen, MD Multiple Sclerosis Center

UPDATE ON MULTIPLE SCLEROSIS

Case Challenges in MS: Tailoring Therapy to Patient-Specific Characteristics

PMH: No medications; Immunizations UTD No hospitalizations or surgeries Speech Delay. Birth Hx: 24 WGA, NICU x6 months

Patologie infiammatorie encefaliche e midollari

MRI in Multiple Sclerosis Features of Cerebral Atrophy with special focus on Multiple Sclerosis. E.W. Radue K. Bendfeldt Till Sprenger

Neurological Assessment for Multiple Sclerosis and Extended Disability Scale Score

Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis

Program Highlights. A multidisciplinary AAN working group identified areas for improvement in the diagnosis and management of patients with MS

MEDIA BACKGROUNDER. Multiple Sclerosis: A serious and unpredictable neurological disease

MULTIPLE SCLEROSIS PROFILE

Idiopathic Inflammatory Demyelinating Diseases of the Brainstem

Demyelinating Diseases of the Brain

Tony Traboulsee, MD Associate Professor (Medicine/Neurology) Head, UBC MS and NMO Programs. MRI Diagnostic Red Flags

Workshop II. How to manage highly active MS patients in practice?

Myelitis. Case 2. History. Examination. Mahtab Ghadiri

Interactive Cases: Demyelinating Diseases and Mimics. Disclosures. Case 1 25 yo F with nystagmus; look for tumor 4/14/2017

Pediatric MS treatments: What do you start with, when do you switch?

New Insights on Optic Neuritis in Young People

COPYRIGHT 2012 THE TRANSVERSE MYELITIS ASSOCIATION. ALL RIGHTS RESERVED

Adv Pathophysiology Unit 2: Neuro Page 1 of 8

Update in Multiple Sclerosis

Title: Recurrent myelitis after allogeneic stem cell transplantation. Report of two cases.

PEDIATRIC MULTIPLE SCLEROSIS

Le Hua, MD. Disclosures Teaching and Speaking: Teva Neurosciences, Genzyme, Novartis Advisory Board: Genzyme, EMD Serono

Innovazione e personalizzazione nella terapia della SM. Rocco Totaro Centro per la Diagnosi e Cura delle Malattie Demielinizzanti L Aquila

Tumefactive multiple sclerosis lesions: Diagnostic challenge for the radiologist

Progress in the field

Th1/Th17 Cytokine Dysregulation during Different Stages of Multiple Sclerosis

MYELITIS. A Mochan Neurology

Wingerchuk et al, Neurol, 2006

Central nervous system demyelinating diseases - Multiple sclerosis -

Multiple sclerosis. Tünde Csépány MD. PhD. 08. November 2017.

1 MS Lesions in T2-Weighted Images

MRI in MS: the radiologist perspective

Multiple Sclerosis Diagnosis And Therapy

MRI in MS. MRI in multiple sclerosis. MS T2 Lesions: Pathology. Brain lesions Morphology Matters. Sagittal FLAIR Morphology Matters

Vague Neurological Conditions

Nicole E Stanley, MD Anatomic and Clinical Pathology, PGY-3

Multiple Sclerosis. Biology 12 Nervous System Project

Role of MRI in acute disseminated encephalomyelitis

NEW DIAGNOSTIC CRITERIA FOR MULTIPLE SCLEROSIS

Mitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA

CNS pathology Third year medical students. Dr Heyam Awad 2018 Lecture 4: Myelin diseases of the CNS

Multiple Sclerosis , The Patient Education Institute, Inc. nr Last reviewed: 04/17/2017 1

Multiple Sclerosis. Multiple Sclerosis. Worldwide Prevalence of MS. Epidemiology. History. Potential Triggers for MS. Definition:

Neuroimmunology. Innervation of lymphoid organs. Neurotransmitters. Neuroendocrine hormones. Cytokines. Autoimmunity

Guideline for the use of beta-interferons in patients with multiple sclerosis a South African proposal

Vesicular Demyelination in MS A Pattern of Humoral Immune Pathology Multiple Sclerosis: B-Cells Take Center Stage

Hematopoietic Stem Cell Transplantation for Adrenoleukodystrophy

Myelitis. Myelitis. Multiple Sclerosis (MS) Acute demyelinating syndrome (ADS) Indictions for spinal cord MRI in MS.

Biologics and Beyond: Treatment of Multiple Sclerosis. Rita Jebrin, PharmD, BCPS

Actualização no diagnóstico e tratamento das doenças desmielinizantes na infância. Silvia Tenembaum

Neurology and Neurometabolic Unit Department of Neurological and Behavioral Sciences University of Siena Siena, Italy

Roadmap to Pediatric Demyelination: Clinical Features. Teri Schreiner, MD MPH June 1, 2014 CMSC. Disclosures

RESEARCH/CLINICAL UPDATE. ADDITIONAL ROUTING Research Advocate Staff Liaison Chapter President I & R specialists


Clinical, Laboratory and Radiological Predictors of Outcome in Relapsing Remitting Multiple Sclerosis

Content. Polyarteritis nodosa. Vasculitis. Giant cell arteritis. Primary cerebral angiitis. Other autoimmune CNS disease.

MS Academia: Multiple sclerosis advanced course

Fast Facts: Multiple Sclerosis

Clinically isolated syndromes (CIS) may

Dean Shibata, M.D. Department of Radiology, University of Washington. White Matter, Metabolic, and Degenerative Disease.

The Neurology of HIV Infection. Carolyn Barley Britton, MD, MS Associate Professor of Clinical Neurology Columbia University

Contents 1 Immunology for the Non-immunologist 2 Neurology for the Non-neurologist 3 Neuroimmunology for the Non-neuroimmunologist

Magnetic Resonance Imaging in the Acquired Demyelinating Disorders: A Pediatric Cohort Study

Multiple sclerosis in Japan: Nationwide surveys over 30 years

Progressive Multiple Sclerosis

Endpoints in a treatment trial in NMO: Clinician s view. Anu Jacob Consultant Neurologist The Walton Centre, Liverpool,UK

Multiple Sclerosis (MS) is a

CME Conference: Updates in Neuro ophthalmology and MS March 2017 Teri Schreiner, MD MPH University of Colorado

A pictorial review of neurological complications of systemic lupus erythematosus and antiphospholipid syndrome

Radiologic-Pathologic Correlation of White Matter Disease

Neurosarcoidosis. Walter Royal, III, MD Professor of Neurology and Anatomy and Neurobiology University of Maryland School of Medicine

PRIMARY DISEASES OF MYELIN. By: Shifaa Al Qa qa

Transcription:

MULTIPLE SCLEROSIS Update E. Torage Shivapour, M.D. Clinical Professor Department of Neurology University of Iowa Hospitals & Clinics

Disclosures I do not have any disclosures.

Multiple Sclerosis Most common demyelinating disease of the CNS > 90% affected prior to age 55 < 5% diagnosed before the age of 14 Multifocal with lesions of different ages, time and site Relapsing and remitting (80%) vs progressive course (15%), focal single lesion (<5%) Classification: Classic ( Charcot type) Acute (Marburg type) Concentric sclerosis (Balo s type). Very rare Schilder s disease occurs in children, extensive demyelination, acute, can be remitting, responds to steroids.

Jean Martin Charcot (1825-1893)

Who gets MS? Each week, about 200 Americans are diagnosed with MS 1 Most people are diagnosed between the ages of 20 and 50 (average age, 31-33) 1,2 More than twice as many women have MS as men 1 MS is more common in Caucasians, especially those of northern European descent 1 1. National MS Society. Just the Facts: 2006-2007. Available at: www.nmss.org. 2. MS Network. Who Gets MS? Available at: www.ms-network.com.

MS: Magnitude of the Problem

Epidemiology of MS Individuals who migrate to high risk area before age 10 have a high risk for disease Individuals who migrate to low risk area before age 10 assume a low risk for disease Individuals who migrate after the age of 10 assume the risk of the area in which they spent their first 10 years

Birth Month and Risk of MS N = 17,874 Canadian patients with MS Significantly fewer patients with MS were born in November (p=.009) and more were born in May (p<0.0001) compared with other months Vitamin D influences the expression of HLA-DRB1*15 Willer CJ (Br Med J 2005) Ramagopalan, S.V. (AAN, December 10, 2009)

Potential Triggers for Multiple Sclerosis Genetic predisposition Infectious agent Abnormal immunologic response Environmental factors MS MS = multiple sclerosis Gilden DH Lancet Neurol 2005;4:195-202, Noseworthy et al. N Engl J Med 2000;343:938

Genetic Prevalence of MS In a recent genome wide transcription analysis for MS, 48 new genetic variants were identified Of interest most genes reverted back during pregnancy. (Nature Genetics, September 2013)

Genetic Prevalence of MS 10 X increase for MS if direct relative affected Siblings of an affected person have a 2-5% risk of developing MS. Higher prevalence in identical twins Variability in severity of disease in twins and affected relatives

EBV and Children Children with MS demonstrate abnormally increased rates of EBV viral reactivation and a broader range of genetic variants, suggesting a selective impairment in their immunologic control of EBV. Yea, C (AAN, Oct 15, 2013)

Update on IM and MS Research on EBV has continued to evolve. Latest findings shows that it is unlikely any of the studied polymorphisms contribute to explaining association between anti-ebna1 Ab titer or history of IM and MS. Simon, KC (Multiple Sclerosis and Related Disorders, 2015)

Natural History of MS

MR Imaging in MS

Gd enhancement T1 black hole Brain atrophy (shrinkage) T2 lesion Spinal cord lesion

47 year old female; RN

MRI Findings in the Diagnosis of MS MRI Findings Supporting the Diagnosis of MS Lesion size > 5 mm in diameter Lesion shape ovoid or oval Lesion location Periventricular, perivenular (Dawson s fingers), juxtacortical, corpus callosum, intratentorial, spinal cord Homogeneous or open ringenhancing Presence of T1 black holes MRI Findings cautioning against the Diagnosis of MS Lesion size smaller, many or all 5 mm in diameter Lesion shape linear, punctate, comma, subtle Lesion location lack of periventricular involvement Meningeal/basilar enhancement Normal scan of brain and spinal cord

Oligoclonal bands are more sensitive and specific (90-95%). IgG index or IgG synthesis are sensitive and specific (70-75%).

MS: Clinical Subtypes

Differential Diagnosis of MS Inflammatory diseases SLE Sjogren s disease Behcet s disease Polyarteritis nodosa Granulomatous angitis Sarcoidosis Paraneoplastic encephalomyetopathies Infectious diseases Lyme disease HTLV-1 PML HIV myelopathy/encephalopathy Neurosyphilis Disease of myelin ALD ADEM Central pontine myelinolysis Vascular Lacunes Embolic CADASIL Stroke due to APLA Miscellaneous Spinocerebellar disorders Cervical spondylosis Arnold-Chiari malformation Syrinx Vitamin B12 deficiency Hashimoto Thyroiditis Leber s Optic Atrophy

Clinical Presentations of MS

Multiple Sclerosis: Common Symptoms Symptom Prevalence, % Bladder symptoms 90 Fatigue 80 Spasticity 70 Sexual dysfunction 64 Pain 62 Cognitive dysfunction 50 in 15 yrs, 90 in 25 yrs Depression 50 Bowel dysfunction 40 Goodin et al. Mult Scler. 1999; 5:78-88.

Fatigue in MS Probably the single most common symptom shared by patients with MS Reported > 75% of patients In 30% of patients, it occurs before other symptoms of the disease In many patients, fatigue is the most disabling symptom and one of the most common reasons for retirement due to disability

Depression and Multiple Sclerosis Does MS cause depression? Does the therapy for MS (specifically IFN) cause depression? How is depression best managed?

Cognitive Impairment in Untreated MS Occurs in approximately half of all people with MS Often under recognized or misdiagnosed as depression, stress, or personality disorder Impairs daily functioning of people with MS Leading cause of unemployment in persons with MS

(ACTRIMS, Summer 2014)

Mesenchymal Stem Cells as a Treatment for MS Mesenchymal stem cells (MSCs) could reduce inflammatory lesions in patients with MS. MSCs can be derived from bone marrow or placenta. (Neurology Reviews, July 2013)

Complementary & Alternative Medicine in MS The guidelines demonstrate that even though there are multiple CAM therapies, there is little evidence that most of them are effectively treating MS. (Neurology Today, 2014)

Functional brain abnormalities linked to cognitive impairments in MS patients who use Marijuana Medical Marijuana does not appear to have curative effects on any neurologic condition, but it may ameliorate unwanted symptoms and ease suffering. Hurley (Neurology Today, 2014) Fife (AAN, 2015)

Vitamin D Vitamin D is a protective factor in MS For every 10 ng/ml increase in Vitamin D levels in patients with MS, their EDSS scores were 0.05 points lower. Recommended Vitamin D levels of 50-80 ng/ml. Otto, A (Clinical Neurology News, June 2012)

Additional CAM Therapies Ginkgo biloba Ginseng Omega-3 fatty acid (anti-inflammatory) Omega-6 fatty acid (pro-inflammatory)

Medical Management During Pregnancy, Delivery, and Postpartum None of the disease-modifying medications are approved for use during pregnancy. The disease-modifying drugs are also not recommended for use during breastfeeding. Women with MS usually do not need special gynecologic care during pregnancy, labor and delivery.

Conclusion MS is the most common demyelinating disease of the CNS. Relapsing remitting (80%), Progressive (15%), Focal Single Lesion (< 5%) 200 Americans (primary between ages 20-50) diagnosed weekly with MS. More than twice as many women have MS than men. Less than 10% of all MS patients are younger than age 18. 10% increase for MS if direct relative affected.

Conclusion (con t) Correlation between EBNA-1 IgG and gadolinium enhancing lesions in MS disease activity. Patients need to undergo an MRI and CSF for oligoclonal bands and IgG index/synthesis. Diagnosing MS is still a clinical diagnosis (no single diagnostic laboratory test).

Conclusion (con t) Common symptoms include neurogenic bladder, fatigue, spasticity, sexual dysfunction, pain, cognitive dysfunction, and depression. There are several different types of injectable and oral medications for treatment.

Take Home Message Patients do not care about how much you know. What they want to know is how much you care!

Thank you! Q & A